Dr. Masatoshi Kudo from Faculty of Medicine, Kindai University, has lead a research team to implement clinical trials for liver cancer treatment, which showed a remedy (TACE: transcatheter arterial chemoembolization) in combination with sorafenib (molecular-targeted drug) significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).
Dr. Kudo expects the treatment will be a standard of care in patients with intermediate-stage HCC.

Source
https://gicasym.org/daily-news/tactics-trial-demonstrates-success-tace-plus-sorafenib-unresectable-hcc